CN Patent

CN102026626B — 包含草酸艾司西酞普兰的颗粒

Assigned to Hexal AG · Expires 2013-01-09 · 13y expired

What this patent protects

本发明涉及包含具有小于100μm的平均粒径的草酸艾司西酞普兰和至少一种填充剂的颗粒。本发明进一步涉及制备所述颗粒的方法，也涉及包含所述颗粒的片剂或胶囊，和/或通过压制所述颗粒以形成片剂或通过将所述颗粒填充到胶囊壳中而获得的片剂或胶囊。最后，本发明涉及所述颗粒和/或片剂或胶囊在治疗或预防选自抑郁性疾病的病症中的用途。

USPTO Abstract

本发明涉及包含具有小于100μm的平均粒径的草酸艾司西酞普兰和至少一种填充剂的颗粒。本发明进一步涉及制备所述颗粒的方法，也涉及包含所述颗粒的片剂或胶囊，和/或通过压制所述颗粒以形成片剂或通过将所述颗粒填充到胶囊壳中而获得的片剂或胶囊。最后，本发明涉及所述颗粒和/或片剂或胶囊在治疗或预防选自抑郁性疾病的病症中的用途。

Drugs covered by this patent

osilodrostat-phosphate (OSILODROSTAT PHOSPHATE)

Patent Metadata

Patent number: CN102026626B
Jurisdiction: CN
Classification: —
Expires: 2013-01-09
Drug substance claim: No
Drug product claim: No
Assignee: Hexal AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.